"The Biggest Scandal Since Lobotomies" - Tavistock Whistleblower Marcus Evans
27 November 2025
With Marcus Evans
UK
Marcus Evans resigned as a Tavistock governor in 2019 after six months of challenging its gender service leadership — years before the Cass Review confirmed what he and earlier whistleblowers had warned. A psychoanalyst with more than four decades of NHS experience, Evans argues that affirming gender dysphoria without rigorous therapeutic scrutiny is clinically indefensible, that the NHS puberty-blocker trial is structurally too short to yield reliable evidence, and that the scale of institutional failure belongs in the history of medicine's worst collective errors.
Marcus Evans spent more than four decades in NHS psychiatry and psychoanalysis, including as Associate Clinical Director of the Adult Department at the Tavistock and Portman NHS Trust. He resigned as a Trust governor in 2019 after months of raising concerns about the Gender Identity Development Service and finding them dismissed. The Cass Review, published in 2024, ultimately vindicated what Evans and others had warned: that GIDS had operated without an adequate evidence base and failed thousands of young patients. The whistleblower history at Tavistock stretches back further than most accounts acknowledge. Evans traces a chronology running more than two decades: his wife Sue Evans raised concerns in 2005 and later initiated the judicial review that became foundational to legal challenges over puberty blockers; a 2006 internal report predicted with considerable accuracy what the Cass Review would later confirm; Dr David Bell documented staff distress and clinical dysfunction in 2018; and Marcus Evans resigned in 2019. That sequence raises an uncomfortable question about how long the NHS and its regulators were in a position to act, and did not. The clinical argument at the centre of the conversation is Evans's contention that affirming a patient's gender identity, without the scrutiny applied to any other presenting belief, constitutes a form of collusion. He draws a deliberate analogy with anorexia: a therapist does not validate the anorexic's conviction that food is harmful; the task is to understand why that belief has taken hold. He argues that gender dysphoria in adolescents often functions as an overvalued belief — totalising and resistant to clinical questioning — and notes that therapists have privately acknowledged walking into exactly that collusion with their patients. Evans is sharply critical of the NHS England puberty-blocker trial currently underway. He argues that two years is wholly inadequate to assess the long-term developmental consequences of blocking adolescent puberty. Meaningful evaluation requires following patients into midlife — observing outcomes for those who have forgone fertility or undergone irreversible surgery. A trial designed on that timescale cannot answer the questions that matter most, and he regards it as evidence that the lessons of the GIDS era have not been adequately absorbed. The comparison to lobotomies is not rhetorical excess. Evans is placing gender medicine within a tradition of interventions performed with institutional confidence on vulnerable patients, later recognised as catastrophic. Britain is at an unusual juncture: the Cass Review has provided an authoritative public reckoning, NHS England has suspended routine puberty-blocker prescribing, and courts have clarified the consent framework for minors. What Evans adds to that picture is the clinical interior of the story — what signals were suppressed inside the Trust, and what the profession now owes to those treated during those years.
